Abstract 34P
Background
Androgen receptor-positive breast cancer, characterized by overexpression of androgen receptors (ARs), is attracting attention as a subcategory of triple-negative breast cancer (TNBC). The involvement of androgen signaling and the presence of endocrine activity in these TNBC cells make them potential treatment targets. Recent improvements in metabolomics measurement techniques have also revealed the metabolic characteristics of cancer cells. Different cancer cell subtypes exhibit different metabolic balances, and it is believed that a shift to aerobic glycolysis occurs in TNBC, although oxidative phosphorylation has been heavily implicated in endocrine-dependent breast cancer. In this study, we used metabolomics to investigate metabolic regulatory mechanisms in androgen receptor-positive TNBC.
Methods
We introduced ARs into the MDA-MB-231 strain of TNBC cells by using the pEGFP-C1-AR plasmid vector, establishing a stable AR-forced expression TNBC line (MDA-MB-231-AR). Positively ionized metabolites were purified from the parental cell line and the AR forced expression cell line. Metabolome analysis was conducted using a capillary electrophoresis–mass spectrometer (CE-TOFMS/-QqQMS). Data analysis was carried out by extracting, cross-checking, and ordering peaks using MasterHands.
Results
Hierarchical clustering analysis of metabolite peak values showed that the MDA-MB-231-AR strain had improved biological malignancy compared to the parental strain. An evaluation of energy metabolism pathways (the glycolysis system, the pentose phosphate pathway, and tricarboxylic acid cycle) showed that the MDA-MB-231-AR strain had a higher NADH/NAD+ ratio and a lower lactic acid/pyruvic acid ratio than the parental strain, suggesting improved hypoxic metabolism. The glutathione/oxidized glutathione ratio was also lower in the MDA-MB-231-AR cell line than in the parental strain, indicating release from oxidative stress.
Conclusions
Improved hypoxic metabolism was observed in the energy metabolism pathways of AR-positive TNBC cells. This suggests a possible shift from aerobic glycolysis to oxidative phosphorylation might in TNBC cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract